Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties

被引:59
|
作者
Ulrich, Silvia
Fischler, Manuel
Speich, Rudolf
Popov, Vladimir
Maggiorini, Marco
机构
[1] Univ Zurich Hosp, Dept Internal Med, Div Resp, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Div Crit Care Med, CH-8091 Zurich, Switzerland
[3] Clin Pulm Med & Rehabil, Barmelweid, Switzerland
关键词
chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; pulmonary hemodynamics; pulmonary vascular compliance; vasoreactivity testing;
D O I
10.1378/chest.130.3.841
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are the major classes of pulmonary hypertensive disorders according to the World Health Organization; both lead to right heart failure and death. A better understanding of disease mechanisms has led to the suggestion that the thromboembolic and nonthrombo-embolic types of pulmonary hypertension may share pathophysiologic features. We therefore compared acute vasoreactivity and proximal pulmonary artery compliance in patients with PAH and CTEPH during the initial diagnostic heart catheterization. Methods: Right heart catheterization using a flow-directed Swan-Ganz catheter was performed in patients with CTEPH (n = 22) and PAH (n = 35). Pulmonary hemodynamics were assessed at baseline, during the inhalation of 40 ppm of nitric oxide, and 30 min after the inhalation of 10 mu g of iloprost. To assess the proximal pulmonary artery compliance, the pulse pressure (PP) [systolic - diastolic pressure] and the fractional PIP (PPf) [divided by the mean pressure] were calculated. Results: Both vasodilators produced similar hemodynamic improvement, and the difference between CTEPH and PAH was not significant. The baseline PP and PPf did not vary between the two groups. Conclusion: Patients with PAH and CTEPH show similar acute vasoreactivity to inhaled nitric oxide and iloprost, and have similar pulmonary artery compliance. These findings support the presence of some shared pathophysiologic pathways in both disorders and may lead to therapeutic implications in patients with inoperable CTEPH.
引用
收藏
页码:841 / 846
页数:6
相关论文
共 50 条
  • [1] Acute pulmonary vasoreactivity in chronic thromboembolic pulmonary hypertension (CTEPH)
    Skoro-Sajer, N.
    Sadushi, R.
    Bonderman, D.
    Jakowitsch, J.
    Kneussl, M.
    Klepetko, W.
    Lang, I.
    EUROPEAN HEART JOURNAL, 2007, 28 : 632 - 632
  • [2] Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension
    Xu, Qi-Xia
    Yang, Yuan-Hua
    Geng, Jie
    Zhail, Zhen-Guo
    Gong, Juan-Ni
    Li, Ji-Feng
    Tang, Xiao
    Wang, Chen
    CHINESE MEDICAL JOURNAL, 2017, 130 (04) : 382 - +
  • [3] Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension
    Xu Qi-Xia
    Yang Yuan-Hua
    Geng Jie
    Zhai Zhen-Guo
    Gong Juan-Ni
    Li Ji-Feng
    Tang Xiao
    Wang Chen
    中华医学杂志英文版, 2017, 130 (04) : 382 - 391
  • [4] Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension
    Yu, Yan-Zhe
    Yuan, Ping
    Yang, Yi-Lan
    Sun, Yuan-Yuan
    Zhao, Qin-Hua
    Wang, Lan
    Jiang, Rong
    Wu, Wen-Hui
    He, Jing
    Dai, Jing-Hong
    Li, Yuan
    Pudasaini, Bigyan
    Li, Jin-Ling
    Gong, Su-Gang
    Xie, Wei-Ping
    Liu, Jin-Ming
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (03): : 959 - 973
  • [5] Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Kambakamba, Adrian
    Tello, Khodr
    Axmann, Jens
    Gall, Henning
    Ghofrani, Ardeschir
    Guth, Stefan
    Wiedenroth, Christoph
    Richter, Manuel Jonas
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [6] Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features
    Hoette, S.
    Creuze, N.
    Rochitte, C. E.
    Simonneau, G.
    Humbert, M.
    Souza, R.
    Chemla, D.
    PULMONOLOGY, 2019, 25 (04): : 248 - 251
  • [7] Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
    Humbert, M.
    EUROPEAN RESPIRATORY REVIEW, 2010, 19 (115): : 59 - 63
  • [8] Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Bishop, Bryan M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (21) : 1839 - 1844
  • [9] Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Anderson, Ryan J.
    Malhotra, Atul
    Kim, Nick H.
    JOURNAL OF THORACIC DISEASE, 2016, 8 : S562 - S565
  • [10] Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
    Koudstaal, Thomas
    Boomars, Karin A.
    Kool, Mirjam
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)